18F-FDG PET/CT in treatment response evaluation of Burkitt lymphoma: complete remission of a peritoneal super scan

Hell J Nucl Med. 2020 Jan-Apr;23(1):76-78. doi: 10.1967/s002449912006. Epub 2020 Mar 31.

Abstract

Peritoneal lymphomatosis, defined as the disseminated intraperitoneal lymphomatous infiltration, is a rare presentation usually of non-Hodgkin lymphoma and is associated with aggressive histological subtypes of the malignancy. Recently, the term "peritoneal super scan" has been introduced in positron emission tomography/computed tomography (PET/CT) in a patient with Burkitt lymphoma to describe hypermetabolic lymphomatous involvement of the entire peritoneum, leading to suppression of tracer uptake in organs with otherwise normally increased fluorine-18-fluorodeoxyglucose (18F-FDG) uptake. Herein, we report on a patient with Burkitt lymphoma, initially presenting with a peritoneal super scan in PET/CT demonstrating complete metabolic response to R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone) therapy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Burkitt Lymphoma / diagnostic imaging*
  • Burkitt Lymphoma / drug therapy*
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Peritoneum / diagnostic imaging*
  • Positron Emission Tomography Computed Tomography*
  • Prednisone / therapeutic use
  • Rituximab / therapeutic use
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • R-CHOP protocol
  • Fluorodeoxyglucose F18
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone